SCHEMBL1798684

SCHEMBL1798684

COC(=O)c1ccc(CN2C(=O)C(C(C)C)NC23CCN(C(=O)c2cc(C(C)(C)C)nn2C)CC3)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.40
NAA50 Q9GZZ1 3/20 0.37
LMNA P02545 3/20 0.36
RAB9A P51151 3/20 0.36
HTT P42858 2/20 0.36
NPC1 O15118 1/20 0.36
GALR3 O60755 2/20 0.35
TSHR P16473 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
EPHX2 P34913 1/20 0.34
MAPT P10636 2/20 0.34
TP53 P04637 1/20 0.34
DGAT2 Q96PD7 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
CHKA P35790 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1799198 0.82 LMNA (0.39) LMNARAB9AHTTNPC1OPRD1
SCHEMBL1800776 0.79 GPR183 (0.42) LMNARAB9AHTTNPC1OPRD1
SCHEMBL1799799 0.78 CYP2C19 (0.41) LMNARAB9AHTTNPC1OPRD1
SCHEMBL3928978 0.75 LMNA (0.41) LMNARAB9AHTTNPC1TSHR
SCHEMBL3915520 0.75 HRH3 (0.48) LMNARAB9AHTTNPC1TSHR
SCHEMBL3916498 0.75 GAA (0.44) LMNARAB9AHTTNPC1MAPT
SCHEMBL3914913 0.75 GAA (0.41) LMNARAB9AHTTNPC1MAPT
SCHEMBL3926266 0.74 MAPT (0.47) LMNARAB9AHTTNPC1MAPT
SCHEMBL3916428 0.74 KDM4E (0.42) LMNARAB9AHTTNPC1OPRD1
SCHEMBL3918951 0.74 LMNA (0.44) LMNARAB9AHTTNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 NAMPT 2046/4885NAA50 344/4885LMNA 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.